Oncotarget is considered one of the most insightful peer review journals in the medical community today. As the work of Dr. Blagosklonny continues, the popularity of the journal continues to grow at breakneck speed. Those who work with Dr. Blagosklonny and read his work know that they are reading the best of his research and time spent working on ways to improve cancer treatment and prevent it as well. His work has been noted as constructive, punctual, and above all insightful by his peers as they read, research and attempt to raise the bar on their own clinical investigations.
This journal is also privileged to call on the help of Nobel Prize winner, Andrew Schally, and Carlo Croce, the Former Editor-in-Chief of Cancer Research. Having published multiple works in the Oncotarget journal, means that it is packed with tons of information that is ready to be read and researched by other oncologists around the world. Dr. Blagosklonny continues to involve some of the foremost researchers on cancer research, and is continually accepting papers regarding topics that are often published in the journal. There are other conditions related to aging that are submitted to the journal, and are often researched alongside cancer for clues and further study on how this may impact their condition and overall health. Read more about Oncotarget at Bioxbio.
Those who are seeking to be a part of a prestigious peer review journal need look no further. Oncotarget follows COPE, the Code of Conduct and Best Practice Guidelines to ensure that they can uphold the scholarly reputation that Dr. Blagosklonny has built with his career and this journal as a whole. The process used to determine whether or not research can be published is based upon whether or not it has strong scientific merit, as well as the technicality used to write up the research for the journal.
It is upon a final presentation and review that the journal publishes with the greatest care. Taking great care and discretion with this journal has been helpful in building confidence for those who read the journal as well as those who submit to the journal. Oncotarget is also available on Dove Press.